for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Richter Gedeon Vegyeszeti Gyar Nyrt

GDRB.BU

Latest Trade

5,865.00HUF

Change

15.00(+0.26%)

Volume

270,964

Today's Range

5,820.00

 - 

5,875.00

52 Week Range

4,702.00

 - 

6,020.00

As of on the Budapest Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5,850.00
Open
5,830.00
Volume
270,964
3M AVG Volume
7.21
Today's High
5,875.00
Today's Low
5,820.00
52 Week High
6,020.00
52 Week Low
4,702.00
Shares Out (MIL)
185.99
Market Cap (MIL)
1,090,293.00
Forward P/E
15.44
Dividend (Yield %)
1.71

Next Event

Q4 2019 Richter Gedeon Vegyeszeti Gyar Nyrt Earnings Release

Latest Developments

More

Hungary's Richter Q3 net profit HUF 22.2 bln, beats forecast

Hungary's Richter posts HUF 17.1 bln Q2 net profit

Richter, Allergan extend Cariprazine agreement to Latin America

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Richter Gedeon Vegyeszeti Gyar Nyrt

Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.

Industry

Biotechnology & Drugs

Contact Info

Gyomroi ut 19-21.

+36.1.4314027

https://www.richter.hu/

Executive Leadership

Erik Bogsch

Chairman of the Board of Directors, Member of the Executive Board

Attila Laszlo Chikan

Chairman of the Supervisory Board

William de Gelsey

Honorary Chairman

Gabor Orban

Chief Executive Officer, Member of the Executive Board, Member of the Board of Directors

Gyorgy Thaler

Member of the Executive Board, Development Director

Key Stats

2.11 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, HUF)

2016

389.7K

2017

444.4K

2018

445.5K

2019(E)

479.0K
EPS (HUF)

2016

340.000

2017

275.000

2018

298.590

2019(E)

379.001
Price To Earnings (TTM)
22.02
Price To Sales (TTM)
2.22
Price To Book (MRQ)
1.47
Price To Cash Flow (TTM)
12.68
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
6.74
Return on Equity (TTM)
5.91

Latest News

Latest News

BRIEF-BlackRock Inc lifts Richter stake to 5.58 pct -filing

* RICHTER SHARES FELL HEAVILY OVER PAST WEEKS ON RESTRICTIONS OF KEY MEDICINE ESMYA

BRIEF-Richter sees over 50 pct Esmya sales fall in 2018 -CEO

Richter Gedeon Vegyeszeti Gyar Nyrt CEO Gabor Orban tells press conference:

BRIEF-Richter Q4 net profit misses, Esmya sales beat forecast

* Q4 NET PROFIT HUF 6.6 BILLION ($25.91 MILLION) VERSUS HUF 9.9 BILLION ANALYST FORECAST IN PORTFOLIO.HU SURVEY

BRIEF-Hungary's Richter sees temporary hit from Esmya restrictions

* STILL BELIEVES BENEFIT TO RISK BALANCE OF ESMYA MEDICINE IS POSITIVE -SPOKESWOMAN

BRIEF-EU health agency imposes temporary restrictions on Richter's Esmya medicine

* EUROPEAN MEDICINES AGENCY SAYS RECOMMENDS REGULAR LIVER MONITORING FOR WOMEN TAKING HUNGARIAN DRUGMAKER RICHTER'S ESMYA FOR UTERINE FIBROIDS WHILE ITS REVIEW IS ONGOING

Allergan, Richter's bipolar depression drug succeeds in key trial

Allergan Plc and Hungary's Gedeon Richter Plc said on Monday their drug to treat severe bipolar depression in adults met the main goal of a late-stage study, bringing the them closer to getting another approval for the drug.

Allergan, Richter depression drug succeeds key trial

Allergan Plc and Hungary's Gedeon Richter Plc said on Monday their drug to treat acute bipolar depression in adults met the main goal of a late-stage study, bringing the drugmakers closer to getting an expanded approval for the drug.

BRIEF-Hungary's Richter lifts 2017 operating profit guidance

* Sees 2017 operating profit margin at 15-16 percent versus 14 percent projected earlier –CEO Orban tells press briefing

BRIEF-Hungary's Richter Q3 net profit beats forecast

* Q3 net profit 16.4 billion forints ($61.03 million) versus 14.5 billion forint analyst forecast in survey by financial news website portfolio.hu

BRIEF-Hungary's Richter to buy 160,000 own shares

* To buy 160,000 own shares on Budapest Stock Exchange via UniCredit Bank Hungary

BRIEF-Richter signs licensing deal with Swedish Pharmanest

Richter Gedeon Vegyeszeti Gyar Nyrt said on Thursday:

BRIEF-Richter Q2 net profit HUF 8.4 bln, beats forecast

* Q2 net profit 8.4 billion forints ($32.15 million) versus 7.6 billion in portfolio.hu analyst poll and 17.4 billion a year ago

BRIEF-Hungary's Richter lifts 2017 revenue guidance

* Expects 2017 revenues from U.S. to rise by 10 pct in dollar terms due to higher royalty income -CEO tells press briefing

BRIEF-Evestra has signed a collaboration partnership agreement with Gedeon Richter Plc

* Evestra - announced it has signed a collaboration partnership agreement with Gedeon Richter Plc

BRIEF-Richter, Allergan sign distribution supply agreement for Levosert

* Richter, Allergan sign distribution supply agreement to sell a female medical product in europe - statement

BRIEF-Richter, Allergan announce positive uterine fibroid medicine test

* Hungary's Richter and Allergan announce positive phase III clinical test results for new medicine to treat uterine fibroids.

BRIEF-Allergan and Gedeon Richter announce positive phase III results for Ulipristal Acetate 5 and 10 MG in treatment of Uterine Fibroids

* Allergan and Gedeon Richter announce positive phase III results for Ulipristal Acetate 5 and 10 MG in treatment of Uterine Fibroids

Richter withdraws marketing application for biosimilar drug

Hungarian pharmaceuticals firm Richter <GDRB.BU> has withdrawn its marketing application for one of its biosimilar drugs from the European Medicines Agency in anticipation of a possible negative assessment, the company said on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up